Lenfant Louis, Rouprêt Morgan
Service d'Urologie, Sorbonne Université, GRC n° 5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, 83 Boulevard de l'Hôpital, 75013 Paris, France.
Biol Aujourdhui. 2018;212(3-4):81-84. doi: 10.1051/jbio/2018028. Epub 2019 Apr 11.
Immunotherapy as a treatment of solid malignancy is based on the activation of the immune system against tumor cells. Since 1976, intravesical instillation of Bacillus Calmette-Guérin (BCG) has been used widely for the treatment of non muscle invasive bladder cancer and is nowadays recommended by all scientific guidelines. New targeted systemic immunotherapies and particularly checkpoints inhibitors are now widely used in several different cancers and notably in onco-urology. Immune checkpoint molecule inhibitors have opened the possibility of treatments for cancers and there are already phase 2 and 3 trials running with or without BCG in localized, muscle invasive and metastatic bladder cancer.
免疫疗法作为实体恶性肿瘤的一种治疗方法,是基于激活免疫系统对抗肿瘤细胞。自1976年以来,卡介苗(BCG)膀胱内灌注已被广泛用于治疗非肌层浸润性膀胱癌,如今所有科学指南均推荐使用。新型靶向全身免疫疗法,尤其是检查点抑制剂,目前已广泛应用于多种不同癌症,特别是在肿瘤泌尿学领域。免疫检查点分子抑制剂为癌症治疗开辟了可能性,目前已经有针对局限性、肌层浸润性和转移性膀胱癌开展的、联合或不联合卡介苗的2期和3期试验。